← Retour à la une
États-Unis · Agences & temps réel · PR Newswire

GlycoEra Initiates Phase 1a Trial of GE8820, the First IgG4-Selective Degrader to Enter the Clinic

Publié par PR Newswire · États-Unis il y a 47 min
GlycoEra Initiates Phase 1a Trial of GE8820, the First IgG4-Selective Degrader to Enter the Clinic
PR Newswire

Résumé détaillé

First-in-human trial to evaluate the potential for rapid, deep and selective IgG4 removal Healthy subject data expected in the first half of 2027 to support advancement into a…

First-in-human trial to evaluate the potential for rapid, deep and selective IgG4 removal

Healthy subject data expected in the first half of 2027 to support advancement into a patient trial in multiple IgG4-driven autoimmune diseases

NEWTON, Mass. and WÄDENSWIL, Switzerland, Nov. 16, 2026 /PRNewswire/ -- GlycoEra, a biotechnology company pioneering precision immunology through the selective removal of disease-driving proteins, today announced that it has initiated dosing of healthy subjects in a Phase 1a clinical trial of GE8820, the first IgG4-selective extracellular protein degrader to enter clinical development. GE8820 is designed to rapidly, deeply and selectively remove disease-driving IgG4 antibodies while preserving other protective immunoglobulins.

"Not all protein degraders are created equal. We believe the ability to remove disease-driving proteins rapidly, deeply and selectively will define the leaders in this field," said Ganesh Kaundinya, Ph.D., Chief Executive Officer of GlycoEra. "That's what we've engineered our platform to deliver. With GE8820 now in the clinic as the first IgG4-selective degrader, we're taking an important step toward demonstrating the potential of our approach to redefine treatment for patients with serious autoimmune diseases."

The Phase 1a trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of GE8820 in healthy subjects through single ascending dose (SAD) and planned multiple ascending dose (MAD) evaluations, with intravenous and subcutaneous routes of administration.

In a nonhuman primate study, a single intravenous dose of GE8820 achieved greater than 95% depletion of circulating human IgG4, with maximum depletion in less than a day after dosing. Because IgG4 levels are comparable in healthy subjects and patients with certain IgG4-driven autoimmune diseases, the Phase 1a trial is expected to provide insights into the speed and depth of IgG4 reduction and inform dose selection for subsequent patient…

G…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

À lire aussi